Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer

Radiation Induced Oral Mucositis Clinical Trial

Official title:

Efficacy and Safety of Lappaconitine Adhesive Patch for the Treatment of Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer ： A Randomized, Prospective Single-center Controlled Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03518489
• Other study ID #: FujianCH
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 1, 2018
• Est. completion date: January 1, 2019

Study information

• Verified date: May 2018
• Source: Fujian Cancer Hospital
• Contact: Jing Huang, master
• Phone: 13375001112
• Email: huangjing2567[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical study is to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain and the improvements in QOL of patients with nasopharyngeal carcinoma . To determine if lappaconitine administered prior to radiation therapy reduces the severity of radiation induced oral mucositis pain in patients who have been diagnosed with nasopharyngeal carcinoma.

Description:

This is a randomized, single -center study conducted in China to evaluate Lappaconitine Adhesive Patch in the reduction severity of radiation induced oral mucositis pain in patients receiving solo radiation therapy or chemoradiation therapy for nasopharyngeal carcinoma.

Patients will reveive daily fractions of IMRT (2.0 - 2.2 Gy) to a total of 60 - 72 Gy over approximately 7 weeks, plus cisplatin administered 80 - 100 mg/m2 once every three weeks for 3 doses or 30 - 40 mg/m2 once weekly for 6-7 doses (investigator's choice).

Patients in both arms received Intensity Modulated Radiation Therapy(IMRT) :All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose is 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions.

Patients will be randomized equally to 1 of 2 treatment arms:

Arm A: Lappaconitine Adhesive Patch per day, concurrent with stardard care for oral mucositis Arm B: stardard care for oral mucositis

All patients will be assessed weekly for oral mucositis per WHO grading criteria until the completion of IMRT, and once weekly thereafter (if necessary) for 7 weeks, or until oral mucositis resolves to ≤ Grade 1.

Approximately 200 patients will be enrolled to ensure that roughly 80 patients per arm complete treatments for primary endpoint analysis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 74
• Est. completion date: January 1, 2019
• Est. primary completion date: December 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Newly histologic diagnosis of nasopharyngeal carcinoma without distant metastasis

• Clinical stage III~IVa( UICC (Union International Against Cancer) /AJCC (American Joint Committee on Cancer) TNM staging system 8th edition)

• Karnofsky Performance Status Scale between 60-100

• WBC count = 4×109/L,neutrophil differential count= 1.5×109/L,Hemoglobin = 90g/L, platelet count = 100×109/L

• ALT or AST =2.5×ULN,bilirubin =2.5×ULN,Serum creatinine =1.5×ULN or Serum creatinine clearance=60ml/min

• Sign the informed consent.

Exclusion Criteria:

• Younger than 18 years old or older than 70 years old

• Pregnancy or lactation

• Severe cerebrovascular disease/canker/psychosis/uncontrolled diabetes

• Have suffered from other tumor or now suffering from other tumor

• Have suffered from oral diseases or salivary gland diseases or mow suffering from oral diseases or salivary gland diseases

• Refuse to give up smoking/drinking/betel chewing

• suffering from other active infection diseases and in need of treatment.

Related Conditions & MeSH terms

• Mucositis
• Nasopharyngeal Neoplasms
• Radiation Induced Oral Mucositis
• Stomatitis

Intervention

Drug:
• Lappaconitine Adhesive Patch
to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
• standard care
Standard care will include mouth wash with antibiotics.

Locations

Country	Name	City	State
China	Fujian Cancer Hospital Radiation Oncology Department	Fuzhou	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline Numeric Rating Scale for Pain(NRS scale) at 7 weeks	The pain caused by oral mucositis for all participants was assessed according to Numeric Rating Scale (NRS scale), by which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain. And an 11-point scale where 0 indicates no pain and 10 indicates the worst imaginable pain. The scale for each patient was recorded.	The NRS scale will be assessed weekly during concurrent chemoradiotherapy (CCRT) for 7 weeks
Secondary	Incidence of Severe Acute Oral Mucositis (Grade of CTCAE = 2)	The Oral Mucositis Score of World Health Organization (WHO) was classified based on the changes of patients' oral mucosa and ability to eat, and are classified to 4 grades. WHO scale for oral mucositis (available in: Peterson DE, Boersdoets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of Oncology 2015; 26(supply5). https://doi.org/10.1093/annonc/mdv202 ): Grade 0 = no oral mucositis; Grade 1 = erythema and soreness; Grade 2 = ulcers, able to eat solids; Grade 3 = ulcers, requires liquid diet (due to mucositis); Grade 4 = ulcers, alimentation not possible (due to mucositis).	The WHO score will be assessed weekly during concurrent chemoradiotherapy (CCRT) for 7 weeks.
Secondary	Change from Baseline Quality of Life at 7 weeks	he quality of life for all participants was evaluated according to The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (available in: Grønvold M. EORTC QLQ-C30 Scoring Manual 2014.)	The EORTC QLQ-C30 shoule be completed weekly during concurrent chemoradiotherapy (CCRT) for 7 weeks.
Secondary	Change from Baseline Karnofsky Performance Status Scale at 7 weeks	The functional status for all participants was assessed according to Karnofsky Performance Status Scale (KPS Scale) (available in: Friendlander AH, Ettinger RL. Karnofsky performance status scale[J]. Special Care in Dentistry, 2009, 29(4):147.). The KPS Scale was range from 0 to 100, and were averagely divided into eleven grades begin with 0.	The KPS Scale will be recoreded weekly during concurrent chemoradiotherapy (CCRT) for 7 weeks
Secondary	The Adverse events Related to lappaconitine	The adverse events related to lappaconitine based on medicine specification of lappaconitine was observed and recorded down according to Common toxicity criteria, version 2.0. (available in: Version CTC, Version CTC, Date P, et al. Common toxicity criteria (ctc) 1999.)	The Adverse events Related to lappaconitinewill be recoreded weekly during concurrent chemoradiotherapy (CCRT) for 7 weeks.